Nascent Biotech, Inc. (OTCMKTS:NBIO – Get Free Report) passed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $0.05 and traded as high as $0.06. Nascent Biotech shares last traded at $0.06, with a volume of 79,091 shares traded.
Nascent Biotech Stock Performance
The company’s 50-day moving average is $0.05 and its two-hundred day moving average is $0.07.
Nascent Biotech Company Profile
Nascent Biotech, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer.
Recommended Stories
- Five stocks we like better than Nascent Biotech
- What Are Dividend Achievers? An Introduction
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- How to Calculate Return on Investment (ROI)
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Best Aerospace Stocks Investing
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Nascent Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nascent Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
